BioSpace News Archive

Blade Therapeutics, Inc. today announced the appointment of Bassem Elmankabadi, M.D., as senior vice president of clinical development.

Ventus Therapeutics U.S., Inc. today announced that Michael Crackower, Ph.D., Chief Scientific Officer of Ventus, will be presenting at the 3rd Inflammasome Therapeutics Summit, being held virtually, November 16-18, 2021.

Biocept, Inc. (Nasdaq: BIOC), today announced the presentation of a multi-institutional case series showing that its CNSide™ cerebrospinal fluid assay helps physicians monitor treatment response and detects actionable mutations in patients with metastatic breast cancer and leptomeningeal disease (LMD).

Genelux Corporation, a clinical-stage immunotherapy company, announced an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health, a biotechnology company advancing its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine.

MYND LIFE SCIENCES INC. (“MYND” or the “Company”) (CSE: MYND) (OTC: MYNDF) is pleased to announce its wholly-owned subsidiary MYND DIAGNOSTICS INC. (“MYND Diagnostics”) has commenced clinical research on a testing procedure as an aid for diagnosing and monitoring Multiple Sclerosis (“MS”) utilizing the Company’s proprietary anti-inflammatory peptide (“MAP”) biomarker.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), today applauds the FDA on its recent update to its COVID-19 test policies that aims to increase nationwide access to at-home and point-of-care tests as well as ensure the accuracy and reliability of such diagnostic tests.

“Most notably, we made important progress in our Phase 1 clinical trial with NVG-291 in the third quarter of 2021,” stated Paul Brennan, NervGen’s President & CEO.

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in cancer, today announced that data on BTM-3566, in development for the treatment of hematological malignancies including Diffuse Large B-cell Lymphoma, was selected for an oral presentation at the 63rd Annual Meeting of the American Society of Hematology.

Saladax Biomedical, Inc (Saladax) is pleased to announce an exclusive distribution agreement with HLS Therapeutics Inc. (“HLS”) (TSX:HLS) to distribute five MyCare™ Psychiatry Laboratory Assays used to measure the six most commonly prescribed antipsychotic drugs in Canada.

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the closing of the previously announced underwritten public offering of 28,750,000 shares of its common stock at a public offering price of $1.60 per share, including the exercise in full by the underwriters of their option to purchase up to 3,750,000 additional shares of common stock.